Circulation Reports
Online ISSN : 2434-0790

この記事には本公開記事があります。本公開記事を参照してください。
引用する場合も本公開記事を引用してください。

Recent Trends in Achievement Rates and Time Required for Left Ventricular Reverse Remodeling in Dilated Cardiomyopathy
Masahiro Wanezaki Tetsu WatanabeAtsushi IizukaTomoki KobayashiShunsuke EdamuraTakayuki SugaiHarutoshi TamuraSatoshi NishiyamaRyuhei YamaguchiNaoaki HashimotoYoichiro OtakiDaisuke KutsuzawaShigehiko KatoTakanori ArimotoShunsuke InoueToshiyuki KoSeitaro NomuraIssei KomuroMasafumi Watanabe
著者情報
ジャーナル オープンアクセス HTML 早期公開
電子付録

論文ID: CR-24-0148

この記事には本公開記事があります。
詳細
抄録

Background: Left ventricular reverse remodeling (LVRR) is associated with a good prognosis in patients with dilated cardiomyopathy (DCM), so in this study we examined the achievement rates of LVRR, the time taken to LVRR and the factors associated with LVRR in recent cases of DCM.

Methods and Results: We enrolled 121 patients with DCM. LVRR was defined as a left ventricular ejection fraction ≥40% at follow-up with a ≥10% improvement. LVRR was observed in 82 patients (68%). The median time to LVRR was 208 days. Multivariate analysis revealed that B-type natriuretic peptide (BNP) levels at discharge (per 1-SD increase, odds ratio: 0.483, 95% confidence interval (CI): 0.224–0.963; P=0.0385) and β-blocker dose (per 1-SD increase, odds ratio: 3.379, 95% CI: 1.644–7.702; P=0.0007) were independently associated with LVRR. When the patients were divided into 2 groups according to the first (2007–2017; n=64) and second (2018–2022; n=57) time periods, there was a significantly higher LVRR achievement rate (48.4% vs. 89.5%) and shorter time to LVRR in the second period than in the first.

Conclusions: The LVRR achievement rate in DCM has been increasing, and the time to LVRR has been shortened in recent years. Beta-blocker dose and BNP levels at discharge may be strongly associated with LVRR.

著者関連情報
© 2025, THE JAPANESE CIRCULATION SOCIETY

This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.
https://creativecommons.org/licenses/by-nc-nd/4.0/
feedback
Top